Phase II trial of methyl-gag and melphalan in metastatic adult renal cell carcinoma

Cancer Invest. 1990;8(6):623-4. doi: 10.3109/07357909009018930.

Abstract

A trial of melphalan and methyl-gag was undertaken in 16 patients with metastatic renal cell carcinoma. Among 14 evaluable patients, 6 had stabilization of disease. No significant responses were observed. While both drugs have produced occasional responses in renal cancer, their combination shows no therapeutic advantage.

Publication types

  • Clinical Trial

MeSH terms

  • Adult
  • Aged
  • Antineoplastic Combined Chemotherapy Protocols / adverse effects
  • Antineoplastic Combined Chemotherapy Protocols / therapeutic use*
  • Carcinoma, Renal Cell / drug therapy*
  • Carcinoma, Renal Cell / secondary
  • Female
  • Humans
  • Kidney Neoplasms / drug therapy*
  • Kidney Neoplasms / secondary
  • Male
  • Melphalan / administration & dosage
  • Middle Aged
  • Mitoguazone / administration & dosage

Substances

  • Mitoguazone
  • Melphalan